Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejandra Negro

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The New England Journal of Medicine|June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction CancerYelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.
Journal of Hepatology|April 13, 2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCCLorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Hepatology (Baltimore, Md.)|May 19, 2025
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trialGeorge Lau, Bruno Sangro, Ann-Lii Cheng, et al.
The New England Journal of Medicine|February 21, 2014
Early-onset stroke and vasculopathy associated with mutations in ADA2Qing Zhou, Dan Yang, Amanda K Ombrello, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The New England Journal of Medicine|June 2, 2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction CancerYelena Y Janjigian, Salah-Eddin Al-Batran, Zev A Wainberg, et al.
Journal of Hepatology|April 13, 2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCCLorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
Future Oncology (London, England)|September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
NEJM Evidence|February 6, 2024
Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaGhassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Hepatology (Baltimore, Md.)|May 19, 2025
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trialGeorge Lau, Bruno Sangro, Ann-Lii Cheng, et al.
The New England Journal of Medicine|February 21, 2014
Early-onset stroke and vasculopathy associated with mutations in ADA2Qing Zhou, Dan Yang, Amanda K Ombrello, et al.
Pageof 3